clearance, enhance mucus secretion, attract eosinophils to the airways, and increase vascular permeability producing edema.
1,2 Moreover, in patients with asthma, the airways are 100 to 1000 times more sensitive to inhaled LTD 4 and LTE 4 than the airways of normal subjects. Furthermore, inhaled LTC 4 and LTD 4 increase bronchial reactivity to methacholine or histamine.
3,4 Such response to exogenous leukotrienes indicates the bio logical role of these compounds in asthma. In addition, leukotrienes have been identified in urine, plasma, nasal secretions, induced sputum, and bronchoalveolar lavage fluid from patients with asthma. Urinary LTE 4 measurements can be used to monitor systemic production of cys-LTs. During spontaneous exacerbations of bronchial asthma, 1 controlled 2 partly controlled 3 uncontrolled, which may cause exacerbation of the disease.
Similar criteria are applied to assess the efficacy of treatment (including antileukotriene agents) in the long-term management of asthma. According to the GINA guidelines, 12 5 steps in the intensity of asthma management can be distinguished depending on the severity level of asthma and its control. In all steps a short acting β 2 -agonist may be used as needed: -low-dose inhaled glucocorticosteroid plus long acting β 2 -agonist or -medium-or high-dose inhaled glucocorticosteroids or -low-dose inhaled glucocorticosteroid plus antileukotriene or -low-dose inhaled glucocorticosteroid plus sustained release theophylline step 4 -medium-or high-dose inhaled glucocorticosteroid plus long-acting β 2 -agonist plus antileukotriene or -medium-or high-dose inhaled glucocorticosteroid plus long acting β 2 -agonist plus sustained release theophylline Clinical division of antileukotriene drugs used in asthma and rhinitis Antileukotriene drugs used in asthma and rhinitis include: 1 inhibitors of 5-LO, which inhibit leukotriene bio synthesis: zileuton (Zyflo), used mainly in the USA 2 CysLT1 antagonists: montelukast (Singulair), zafirlukast (Accolate), and pranlukast (Ono), which is used mainly in Japan.
Still investigated (not yet in clinical practice) are the so called FLAP inhibitors that inhibit the 5-LO-activating proteins.
Long-term treatment of bronchial asthma and rhinitis vs. antileukotriene drugs The current GINA (Global Initiative for Asthma) guidelines, 12 the PRACTALL (Practicing Allergology) report on asthma treatment in children, 13 and ARIA (Allergic Rhinitis and its Impact on Asthma) recommendations 14 classify antileukotriene therapeutic agents as a group of drugs controlling the course of the disease.
The choice of medication used in long-term asthma management depends on the level of disease control. From a clinical point of view, the most significant problem concerns the possibility of applying antileukotriene drugs in the long-term treatment of asthma. Depending on life activity limitation, day and night symptoms, need for use of a short-acting β 2 -agonist, lung function (peak expiratory flow/forced expiratory volume in 1 second [PEF/FEV 1 ]), and the number of exacerbations requiring treatment intensification, asthma can be divided into: side effects of antileukotriene drugs Antileukotriene agents are generally well tolerated by patients. In the 1990s, soon after the introduction of cysteinyl receptor antagonists to the market, their association with Churg-Strauss syndrome was reported. 27-31 It could, however, be a result of a reduction in the dose of systemic glucocorticosteroids during antileukotriene treatment of asthma in the course of a not yet diagnosed Churg-Strauss syndrome.
Zileuton has a hepatotoxic effect. Prior to drug administration, liver enzymes in serum have to be examined and their activity during treatment monitored. Drug inter actions have been reported involving zileuton and several other drugs (e.g., terfenadine, warfarin, and theophylline). There -same as step 4 and additionally oral glucocorticosteroid (lowest dose) and/or anti-immunoglobulin E antibodies.
Antileukotrienes are classified according to standing guidelines as a group of drugs controlling the course of asthma. However, inhaled glucocorticosteroids still remain the first-line treatment in chronic asthma. Antileukotriene agents are recommended as alternative treatment to low-dose inhaled glucocorticosteroids in the second level of asthma, or as complementary treatment to glucocorticosteroids, starting from the third level of asthma.
Cysteinyl receptor antagonists in the long-term treatment of asthma Numerous studies have been published that supply evidence for the positive effect of antileukotriene agents in persistent asthma. Cloud et al.
15 have been one of the first to prove the beneficial effect of cysteinyl receptor antagonists in the management of chronic asthma. This double-blind placebo-controlled study was conducted on 136 asthma patients, who received an antileukotriene for 6 weeks. A significant decrease in the intensity of day and night symptoms was observed in comparison with placebo. However, the frequency of clinical symptoms did not reduce. At 6 week, there was an increase in the mean FEV 1 value, but it was not reflected in the daily PEF rate values. Spector et al. 16 provided more evidence for the efficacy of the studied medication group in the long-term management of asthma. Compared with placebo, the investigators noticed a decrease in day and night asthma symptoms (72% of the studied patients), less frequent use of short-acting β 2 -agonist on demand, and higher values of evening lung function parameters (FEV 1 and PEF rate). The multicenter study conducted by Barnes et al. 17 seems to be particularly inter esting. They assessed the efficacy of therapy with cysteinyl receptor inhibitor in comparison with placebo in terms of the frequency of asthma exacerbations. At 13 week, there were significantly fewer asthma exacerbations that required medical inter vention. 17 In a study published in the 1990s, Reiss et al.
18 examined the efficacy of montelukast in comparison with placebo, administered for 3 months to 681 asthma patients. The authors observed an improvement in the evening para meters of lung function and a decrease in the number of days with asthma exacerbation as compared with placebo. Moreover, the number of days without clinical symptoms of asthma increased.
5-lipoxygenase inhibitors in long-term asthma treatment Zileuton, which belongs to this group of drugs, blocks the synthesis of leukotrienes. Its efficacy in chronic asthma compared with placebo was assessed in several clinical trials.
19,20 During treatment, an increase in a FEV 1 value and a smaller risk of asthma exacerbations requiring oral glucocorticosteroids were observed.
are data showing that co-administration of zileuton and warfarin considerably prolongs prothrombin time related to reduced warfarin clearance and increased serum warfarin concentration. summary According to current guidelines, antileukotriene agents are recommended in the long-term treatment of asthma. Antileukotriene drugs reduce the clinical symptoms of asthma, including cough, 32 improve lung function by slight, variable bronchial dilatation, reduce inflammation of the bronchial mucosa, and thus decrease the frequency of asthma exacerbations. 33, 34 In combination with inhaled glucocorticosteroids, they may allow to reduce the dose of steroids used and to control the disease in patients with moderate and severe asthma. [35] [36] [37] [38] [39] Nonetheless, the use of antileukotrienes in adult asthma patients as a single asthma controller is usually less effective than inhaled glucocorticosteroids, 40 -41 although they are an alternative to glucocorticosteroids in the second stage of the disease. Moreover, they are usually less effective than long acting β 2 -agonists in combined therapy.
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